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cannot fuse their mitochondria. These fusion-deﬁcient cells
display slow growth, decreased mitochondrial membrane
potential, and impaired respiratory capacity. These defects
are reversed upon restoration of fusion capability. The
importance of mitochondrial fusion is further underscored
by the fact that two neurodegenerative diseases, Charcot–
Marie–Tooth disease type 2A (CMT) and autosomal dom-
inant optic atrophy (DOA), are caused by mutations in
Mfn2 and OPA1, respectively.To further explore the phys-
iological requirements for mitochondrial fusion, we have
created conditional knockout mice for both Mfn1 and
Mfn2. Interestingly, Mfn2 is required for proper cerebellar
development. When cerebellar primordia is targeted
embryonically, pups display severe problems in balance
and motility, resulting in feeding problems and death by
about two weeks of age. When Purkinje cells, the only eﬀer-
ent processes of the cerebellum, are targeted upon maturi-
ty, they actually degenerate, causing the mice to develop
tremors and wobble while walking. Thus, mitochondrial
fusion is required in the central nervous system along with
the peripheral motor neurons and optic nerve aﬀected in
CMT and DOA.Disruption of both Mfn1 and Mfn2 in
skeletal muscle results in severely runted mice, which die
at around two months of age. Muscle mass is greatly
reduced in these mice, and cross-sectional analysis reveals
signiﬁcantly decreased muscle ﬁber widths. A modiﬁed
Gomori-trichrome stain results in predominantly red
ﬁbers. In addition, a succinate-dehydrogenase (SDH) enzy-
matic assay reveals greatly increased activity in all ﬁbers.
The combination of red ﬁbers and increased SDH activity
is a hallmark of many mitochondrial diseases, suggesting a
common link between deﬁciencies in mitochondrial fusion
and traditional mitochondrial diseases.
doi:10.1016/j.mito.2006.08.012
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Peroxisome proliferator activated receptors (PPARs) are
a family of ligand-activated transcription factors involved in
lipid and glucose metabolism, immune regulation, and cell
diﬀerentiation. PPARa is preferentially expressed in tissues
with high fatty acid utilization like heart and muscle, while
PPARc is found at high levels in adipocytes and other cell
types involved in lipid synthesis and storage. Recent data
highlighted the potential of ﬁbrates, PPARa agonists, in
the correction of inborn errors of fatty acid oxidation.
We investigated the eﬀects of Bezaﬁbrate, a common
hypolipidemic drug acting as a PPARa agonist, Pioglitazone
andRosiglitazone, PPARc agonists used for non-insulin-de-
pendent diabetes on mitochondrial RCC capacities in com-
plex I and IV deﬁcient cell lines. Skin ﬁbroblasts from
patientswith established defects of complex I, IV andnormal
controls were incubated for 72 h with 500 lM–1 mMBezaf-
ibrate, 100–400 nM Rosiglitazone and Pioglitazone, respec-
tively, or the equivalent amount of DMSO (vehicle).
Fibroblasts were harvested and assayed for complex I,
II + III, IV, and citrate synthase. The complex IV enzyme
activities in two deﬁnite COX deﬁcient cell lines remained
unchanged after the treatments even at very high concentra-
tions. The changes in three deﬁnite complex I deﬁciencies
were also minimum while complex I enzyme activities in
two partial deﬁcient cell lines increased up to nearly 50%
after the PPARc treatment. The citrate synthase tended to
increase after the treatment with both PPARa and PPARc
suggesting mitochondrial proliferation. Our data provides
the foundation for possible therapeutic intervention for the
patients with mitochondrial disorders, especially for those
with partially deﬁcient RCC enzymes. Given the skin ﬁbro-
blasts are not mitochondria-rich tissue, the response in mus-
cle tissues to PPAR agonists could be more favorable.
Further study on a variety of proven deﬁcient cell lines will
be necessary to prove the eﬀectiveness of the PPAR agonists
in mitochondrial disorders.
doi:10.1016/j.mito.2006.08.013
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To elucidate the relationship between tumorgenesis and
alterations of the respiratory chain in renal tumors, we
screened renal tumors (malignat renal cell carcinomas
and benign oncocytomas) and the corresponding normal
tissue for somatic mitochondrial DNA (mtDNA) varia-
tions by denaturing HPLC (DHPLC) analysis and mea-
sured enzyme activities of the oxidative phosphorylation
(OXPHOS) and the Krebs-cycle (Br. J. Cancer 2006. 94,
268–74). Sequencing of somatic mutations revealed in
one renal cell carcinoma and one renal oncocytoma an A
to G transition at position 3243, which is known as a fre-
quent cause of MELAS (Mitochondrial Encephalomyopa-
thy with Lactic Acidosis and Stroke-like episodes). RFLP
analysis revealed >95% mutational load in the oncocytoma
tissue but also a preexisting mutation in the normal kidney
tissue of 20%. In the case of the renal cell carcinoma (89%
heteroplasmy) the corresponding kidney tissue was unaf-
fected. Upregulation of the nuclear encoded enzyme activ-
ities of citrate synthase, isocitrate dehydrogenase, and
oligomycine-sensitive ATPase and downregulation of
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mixed nuclear and mitochondrial encoded OXPHOS com-
plexes I, III, and IV was detected. Interestingly, the com-
plex I activity was more severely impaired than the
complex IV activity. The biochemical consequences of the
A3243G mutation in the two tumor tissues are in agree-
ment with the decreased activity of the mitochondrial and
nuclear encoded complex I and IV reported in muscle biop-
sy and ﬁbroblasts of patients with MELAS syndrome. The
A3243G mutation might be sporadically associated with
other tumor types since it was also detected in a colon can-
cer sample (Mitochondrion 2003, 3, 119–124). Further-
more, the presence of the pathogenic A3243G mutation
in the oncocytoma tissue can explain the compensatory
hyperproliferation of mitochondria, which is characteristic
for oxyphilic tumors.
doi:10.1016/j.mito.2006.08.014
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Alterations of mitochondrial DNA (mtDNA) have been
instrumental in studies of human evolution, in population
genetics, and in molecular medicine to link mtDNA varia-
tions to a variety of human diseases of complex etiology
such as asthenozoospermia, multiple sclerosis, optical
stroke, and Parkinson. For each of these applications,
rapid and cost eﬀective assays for mtDNA haplogrouping
are invaluable. Here we describe a hierarchical system for
mtDNA haplogrouping that combines multiplex PCR
ampliﬁcations, multiplex single-base primer extensions,
and capillary-based electrophoretic separation for analys-
ing ten haplogroup-diagnostic mitochondrial single nucleo-
tide polymorphisms (mtSNPs). Speciﬁc primers were
designed to amplify the mtDNA regions containing the
polymorphic sites that characterise each of the major Euro-
pean haplogroups (H, I, J, K, T, U, V, W, X) in two mul-
tiplex PCRs, A and B. Assay A was designed to determine
the most common European haplogroups, H, J, K, T, U,
and included primers to amplify ﬁve PCR fragments
encompassing six informative mtSNPs. Assay B, contain-
ing four mtSNPs, was only used for the remaining haplo-
groups V, W, I, X, not identiﬁed by assay A. To enable
electrophoretic resolution of the diﬀerent primer extension
products, poly-adenosine tails 5–25 nucleotides in length
were included at the 5 0 end of the SNP primers. Using this
rapid and cost-eﬀective mtDNA genotyping method, we
were able to show that within a large, randomly selected
cohort of healthy Austrians (n = 1172), mtDNAs could
be assigned to all nine major European haplogroups. For-
ty-four percent belonged to haplogroup H, the most fre-
quent haplogroup in European Caucasian populations.
The other major haplogroups identiﬁed were U (15.4%),
J (11.8%), T (8.2%), and K (5.1%). The frequencies of
haplogroups in Austria are within the range observed for
other European countries. Our method may be suitable
for mitochondrial genotyping of samples from large-scale
epidemiology studies and for identifying markers of genetic
susceptibility.
doi:10.1016/j.mito.2006.08.015
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The pyruvate dehydrogenase complex (PDC) is integral
to mitochondrial metabolism and energetics. Congenital
PDC deﬁciency leads to lactic acidosis, neurological degen-
eration and early death. Dichloroacetate (DCA), an inves-
tigational compound for such defects, activates the PDC by
inhibiting the reversible phosphorylation of the E1a sub-
unit and decreases its turnover. Primary human ﬁbroblast
cultures from 5 controls and 6 patients with mutations in
the PDC-E1 component were grown in media ±5 mM
DCA, exposed to media containing 15 mM 13C-labeled
glucose, with the aqueous phase of the cell extracts studied
by nuclear magnetic resonance (NMR) spectroscopy. Com-
puter modeling of NMR-derived 13C-glutamate isotopo-
meric patterns estimated relative carbon ﬂow through
tricarboxylic acid cycle-associated pathways and character-
ized eﬀects of PDC deﬁciency on glucose metabolism and
energetics. With the exception of one patient cell-line
expressing an unusual splicing mutation, PDC-deﬁcient
cells had signiﬁcantly higher glucose consumption, lactate
production, and label-derived acetyl-CoA, indicative of
increased glycolysis vs. controls. In all cells, DCA caused
a major shift (40% decrease) from anaplerotic pathways
(e.g., pyruvate carboxylase) toward ﬂux through PDC.
Ignoring the mis-spliced patient, DCA decreased average
glycolysis (29%) in patient cells, but had no eﬀect in control
cells, and did not change lactate production or the nucleo-
side triphosphate to diphosphate ratio (NTP/NDP) in
either cell group. Maintenance of NTP despite reduced gly-
colysis indicates that DCA improved metabolic eﬃciency
by increasing glucose oxidation. This study demonstrates
that NMR spectroscopy provides novel insight into the
biochemical consequences of PDC deﬁciency and the
mechanism of putative therapeutic agents thereon.
doi:10.1016/j.mito.2006.08.016
Abstracts / Mitochondrion 6 (2006) 263–288 269
